Singlomics Biopharmaceuticals Zhuhai Co., Ltd.

This early-phase study tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose, either alone or combined with chemotherapy. Researchers will also loo…